Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences (Nasdaq: PCRX) announced an equity investment in GeneQuine Biotherapeutics to support gene therapy development for osteoarthritis. The initial investment is €2 million, with an additional €4 million contingent on achieving specific milestones related to its lead product, GQ-303. Up to €2.5 million will be in convertible notes. This investment aligns with Pacira's mission to advance non-opioid pain management solutions. GeneQuine’s gene therapy vectors aim to enhance joint function and reduce pain and inflammation.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increase from 2019. The fourth-quarter net product sales for EXPAREL reached $125.3 million, up from $116.9 million in 2019. Daily sales of EXPAREL were at 109% of the previous year's average for Q4 and 111% for December. Despite COVID-19 disruptions, EXPAREL's growth in elective and non-elective procedures highlights its role in non-opioid pain management. The complete financial results will be reported in Q1 2021.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 7:30 AM ET. Investors can access the live audio via the company's website. A replay will be available for two weeks post-event. Pacira is a leader in non-opioid pain management and regenerative health solutions, known for its long-acting local analgesic, EXPAREL®. The company acquired the handheld cryoanalgesia device, iovera⁰, in April 2019 to further its mission of reducing opioid reliance.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales of $38.1 million for EXPAREL and $0.8 million for iovera° in November 2020, marking a continuation of year-over-year growth despite COVID-19 challenges. The company is optimistic about EXPAREL's increasing adoption in outpatient settings and diverse surgical procedures. However, 2020 sales were affected by pandemic-related elective surgery postponements. The firm will provide ongoing updates on sales for greater transparency as market dynamics evolve post-pandemic.
Pacira BioSciences (NASDAQ: PCRX) will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, at 11:30 AM ET. The live audio can be accessed via the company’s Events page. A replay will be available for two weeks post-event.
Pacira is known for its non-opioid pain management solutions, including EXPAREL®, a long-acting local analgesic launched in April 2012, and the iovera⁰ system acquired in 2019 for targeted nerve treatment.
Pacira BioSciences (NASDAQ: PCRX) announced that the European Commission has granted marketing authorization for EXPAREL for managing post-operative pain in adults. This approval is based on four Phase 3 studies that showed EXPAREL significantly reduces pain and opioid consumption after surgery. The marketing authorization covers all EU member states, the UK, Iceland, Norway, and Liechtenstein, with a launch planned for late 2021. Since its U.S. launch in 2012, EXPAREL has been administered to over 7.5 million patients.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $40.7 million and iovera° at $1 million for October 2020. EXPAREL sales grew by 112% year-over-year, marking five consecutive months of growth. Despite challenges from the COVID-19 pandemic affecting elective surgeries, EXPAREL is increasingly used in various surgical procedures. The company plans to continue monthly sales reports to improve transparency regarding COVID-19's impact.
Pacira BioSciences (NASDAQ: PCRX) will present at the 2020 Jefferies Virtual London Healthcare Conference on November 17, 2020, at 2:05 PM GMT (9:05 AM ET). The presentation will be accessible via the company’s events page, with a replay available for two weeks afterward. Pacira is recognized for its commitment to non-opioid pain management solutions, notably through its long-acting local analgesic EXPAREL®, launched in 2012. The company focuses on reducing opioid reliance in healthcare.
Pacira BioSciences (Nasdaq: PCRX) reported a 12% increase in total revenues to $117.5 million for Q3 2020, driven by strong EXPAREL sales, which reached $113.7 million. The net income increased significantly to $130.1 million, aided by a $124.6 million income tax benefit. Operating expenses decreased to $99.9 million, while adjusted EBITDA rose to $34.2 million from $24.8 million a year prior. The company opened a new training facility to enhance pain management practices and reported preliminary September 2020 sales of $39.5 million for EXPAREL. A positive CHMP opinion for EXPAREL was also noted.
Pacira BioSciences, Inc. has launched the Pacira Innovation and Training Center of Tampa (PITT), aimed at enhancing clinician education in non-opioid pain management techniques. The facility features state-of-the-art technology, including ultrasound scanning stations and a large LCD presentation wall. Ongoing workshops will focus on iovera° training, promoting best practices in pain management. Pacira emphasizes the importance of training for improved patient outcomes, reflecting a commitment to shift procedures toward non-opioid solutions. This strategic initiative is expected to contribute to the growing field of regional anesthesia.